AKT1 and breast cancer: Moreover, it has been revealed that several targets and pathways are associated with drug resistance, such as PI3K/Akt signaling in Adriamycin-resistant breast cancer cells (32) as well as Bcr-Abl and NF-κB pathway in imatinib-resistant CML cells (43).